Endocrine Abstracts

Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor that improves survival in advanced melanoma. However, ipilimumab induces immune-related adverse events including hypophysitis and hypopituitarism. We describe one of the largest single centre series of ipilimumab induced hypophysitis.Methods: We retrospectively analysed all patients (n=301) treated with ipilimumab either as a monotherapy or in combination with nivolu...